ARTICLE | Finance

Old-fashioned values

April 24, 2000 7:00 AM UTC

That generosity wasn't provided to Immunex (IMNX), however, which took a $3.4 billion haircut despite beating the Street consensus by a penny, reporting $0.06 EPS. First quarter sales of Enbrel to treat rheumatoid arthritis hit $131.1 million, a 120 percent increase over $59.7 million in the 1999 quarter. The stock closed the week at $37, down $6.875 (16 percent).

Leading the pack was MedImmune (MEDI), which posted first quarter EPS of $0.80, a nickel above Street consensus, due to blow-out sales of Synagis monoclonal antibody to prevent serious lower respiratory tract disease caused by respiratory syncytial virus. Synagis sales were $176.2 million, up 52 percent from $116.2 million in the first quarter last year. MEDI was up $7.375 to $144.875, rewarding it with a $537.7 million increase in market cap to $10.6 billion...